Substance Use Disorders Clinical Trial
— CUSPOfficial title:
The Canadian Underage Substance Use Prevention Trial
NCT number | NCT04198974 |
Other study ID # | CUSP Trial |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 1, 2019 |
Est. completion date | June 2022 |
Despite having made some strides with respect to reducing adolescent drinking rates, illicit substance use and substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. Now, more than ever, there is a pressing need for effective substance abuse prevention in Canada, particularly for those most at risk of developing substance use problems including prescription drug misuse. Clearly, new approaches to prevention (with lower numbers needed to treat) are needed and which translate new research on addiction vulnerability to personalised prevention and early intervention. The PreVenture Program involves brief cognitive-behavioural interventions targeting personality traits from a neurocognitive perspective. While the personality-targeted approach has been shown to be effective in reducing most substance use behaviors, it has yet to be evaluated for its impact on uptake of prescription drug misuse in adolescents. The Canadian Underage Substance use Prevention (CUSP) Trial aims to evaluate the long-term effects of a personality-targeted school-based prevention program on delaying the onset of drug and alcohol use in adolescence over three years across Canada. This is a hybrid effectiveness [E] and implementation-facilitation [IF] trial on delaying the onset of drug and alcohol use in adolescence. In the [E] part, the effects of a personalized prevention program will be tested against usual school-based prevention curricula. PreVenture is delivered through a TtT implementation model with or without [IF], e.g. with ongoing supervision and web-based support. The [IF] package is designed to support long-term sustainability of PreVenture after a community accesses PreVenture training.
Status | Recruiting |
Enrollment | 12500 |
Est. completion date | June 2022 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 16 Years |
Eligibility |
Inclusion Criteria: - Survey: All year 10 students with either active parental consent or youth assent (depending on local site requirements) will be eligible to participate in the survey - PreVenture: Eligibility will include assenting to study protocol and scoring one or more Standard Deviation (SD) above the school's norm on the 23-item Substance Use Risk Profile Scale (SURPS). The SURPS is a 23-item validated tool that assesses four personality dimensions along the internalizing (hopelessness (HOP) and anxiety sensitivity (AS)) and externalizing (impulsivity (IMP) and sensation seeking (SS)) spectrum. It has been shown to predict specific substance use patterns, including cannabis use and non-medical use of prescription drugs. Of those screened in a given year, 1350 (45%) will report elevated personality profiles and will be eligible for intervention. Exclusion Criteria: - Students that do not have either active parental consent or youth assent (depending on local site requirements) will not be eligible to participate in the survey or PreVenture |
Country | Name | City | State |
---|---|---|---|
Canada | Dalhousie University | Halifax | Nova Scotia |
Canada | University of British Columbia Okanagan Campus | Kelowna | British Columbia |
Canada | CHU Sainte-Justine Research Center | Montreal | Quebec |
Canada | Center for Mental Health and Addicitions | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
St. Justine's Hospital | Canadian Institutes of Health Research (CIHR), Center for Addiction and Mental Health, Dalhousie University, University of British Columbia |
Canada,
Conrod PJ, O'Leary-Barrett M, Newton N, Topper L, Castellanos-Ryan N, Mackie C, Girard A. Effectiveness of a selective, personality-targeted prevention program for adolescent alcohol use and misuse: a cluster randomized controlled trial. JAMA Psychiatry. 2013 Mar;70(3):334-42. doi: 10.1001/jamapsychiatry.2013.651. — View Citation
Conrod PJ. Personality-Targeted Interventions for Substance Use and Misuse. Curr Addict Rep. 2016;3(4):426-436. Epub 2016 Nov 4. Review. — View Citation
O'Leary-Barrett M, Mackie CJ, Castellanos-Ryan N, Al-Khudhairy N, Conrod PJ. Personality-targeted interventions delay uptake of drinking and decrease risk of alcohol-related problems when delivered by teachers. J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):954-963.e1. doi: 10.1016/j.jaac.2010.04.011. Epub 2010 Jul 31. — View Citation
Woicik PA, Stewart SH, Pihl RO, Conrod PJ. The Substance Use Risk Profile Scale: a scale measuring traits linked to reinforcement-specific substance use profiles. Addict Behav. 2009 Dec;34(12):1042-55. doi: 10.1016/j.addbeh.2009.07.001. Epub 2009 Jul 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness (primary outcome): Severity of substance use problems | Compare change in severity of substance use problems as measured by CRAFFT score of both arms of PreVenture against TAU using Cohort 2 in all three conditions. The CRAFFT Screening Test is a short clinical assessment tool designed to screen for substance-related risks and problems in adolescents. CRAFFT stands for the key words of the 6 items in the second section of the assessment - Car, Relax, Alone, Forget, Friends, Trouble. CRAFFT employs a skip pattern: participants whose Part A score is "0" (no use) answer the Car question only of Part B, while those who report any use in Part A also answer Part B's five CRAFFT questions. Each "yes" answer is scored as "1" point and a CRAFFT total score of two or higher identifies "high risk" for a substance use disorder. |
Baseline (pre-intervention), 12 months, 24 months | |
Primary | Implementation Facilitation (primary outcome): Severity of substance use problems | Compare change in severity of substance use problems as measured by CRAFFT score after the start of PreVenture intervention using Cohort 3 between both conditions. The CRAFFT Screening Test is a short clinical assessment tool designed to screen for substance-related risks and problems in adolescents. CRAFFT stands for the key words of the 6 items in the second section of the assessment - Car, Relax, Alone, Forget, Friends, Trouble. CRAFFT employs a skip pattern: participants whose Part A score is "0" (no use) answer the Car question only of Part B, while those who report any use in Part A also answer Part B's five CRAFFT questions. Each "yes" answer is scored as "1" point and a CRAFFT total score of two or higher identifies "high risk" for a substance use disorder. |
12 months | |
Secondary | Effectiveness (secondary outcome): Prevalence of binge drinking | Compare change in prevalence of binge drinking of both arms with PreVenture against TAU using Cohort 2 in all three conditions. Change in frequency of binge drinking assessed by a sub-item on the Alcohol Use Disorders Identification Test (AUDIT). Items asks "How often do you have five or more drinks on one occasion?" (5 or more drinks = binge drinking) and the options are [options: 1=Never/2=Less than monthly/3=Monthly/4=Weekly/5=Daily or almost daily]. Higher numbers indicate higher rates of dependence. |
Baseline (pre-intervention), 12 months, 24 months | |
Secondary | Effectiveness (secondary outcome): Frequency of cannabis use | Compare change in frequency of cannabis use of both arms with PreVenture against TAU using Cohort 2 in all three conditions. Change in frequency of cannabis use assessed by asking: "have you ever used cannabis in the last 12 months?" [options: yes/no]. If a student answers "yes", then asked: "how often used in the last 12 months?" [options: 1=monthly or less/ 2=2-4 times a months/ 3=2-3 times per week/ 4=4-6 times per week/ 5=everyday]. Reporting "yes" to 12 month use and reporting more frequent use indicates higher rates of use. |
Baseline (pre-intervention), 12 months, 24 months | |
Secondary | Effectiveness (secondary outcome): Frequency of non-medical prescription drug use | Compare change in frequency of non-medical prescription drug (NMPD) use of both arms with PreVenture against TAU using Cohort 2 in all three conditions. Change in frequency of NMPD use assessed by asking: "have you ever used prescription drugs for non-medical use (without a doctors prescription) in the last 12 months?" [options: yes/no]. If a student answers "yes", then asked: "how often used in the last 12 months?" [options: 1=monthly or less/ 2=2-4 times a months/ 3=2-3 times per week/ 4=4-6 times per week/ 5=everyday]. Reporting "yes" to 12 month use and reporting more frequent use indicates higher rates of use. | Baseline (pre-intervention), 12 months, 24 months | |
Secondary | Effectiveness (secondary outcome): Frequency of illicit substance use | Compare change in frequency of illicit substance use of both arms with PreVenture against TAU using Cohort 2 in all three conditions. Change in frequency of other illicit substance use assessed by asking: "have you ever used the following substances in the last 12 months?" [options: yes/no]. Substances: Solvents, Cocaine, methylenedioxymethamphetamine (MDMA), Methamphetamine, Heroin, Fentanyl, Psilocybin, lysergic acid diethylamide (LSD), Steroids, Phencyclidine (PCP). If a student answers "yes", then asked: "how often did you use this substance in the last 12 months?" for each substance [options: 1=monthly or less/ 2=2-4 times a months/ 3=2-3 times per week/ 4=4-6 times per week/ 5=everyday]. Reporting "yes" to 12 month use and reporting more frequent use indicates higher rates of use. | Baseline (pre-intervention), 12 months, 24 months | |
Secondary | Implementation Facilitation (secondary outcome): Rate of interventions | Compare change in the rate of interventions in Year 4 after the start of PreVenture intervention in Cohort 4 between both conditions. Rate of the intervention will be measured by assessing the number high risk students delivered the intervention. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |